Vesselon Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $150M

  • Investors
  • 3

Vesselon General Information

Description

Developer of immuno-oncology therapies intended to be protected in circulation and actively targeted to tumors using an FDA-approved lipid microsphere drug. The company's therapies are formed at the time of administration, allowing the creation of new complexes from already approved therapeutics, enabling doctors to treat a wide spectrum of cancers and other series of diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Therapeutic Devices
Biotechnology
Drug Delivery
Corporate Office
  • 101 Merritt 7
  • 3rd Floor
  • Norwalk, CT 06851
  • United States
+1 (203) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vesselon Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC $150M 00000 Completed Startup
2. Early Stage VC 19-Aug-2016 00000 00.00 Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 11-Jun-2015 $1M $1M 00.00 Completed Pre-Clinical Trials
To view Vesselon’s complete valuation and funding history, request access »

Vesselon Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00 00 00 00 00.000
To view Vesselon’s complete cap table history, request access »

Vesselon Patents

Vesselon Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230058977-A1 Compositions and methods for targeted delivery of therapeutics using carriers Pending 03-Nov-2020 000000000
AU-2021373731-A1 Compositions and methods for targeted delivery of therapeutics using carriers Pending 03-Nov-2020 0000000000
CA-3197187-A1 Compositions and methods for targeted delivery of therapeutics using carriers Pending 03-Nov-2020 0000000000
EP-4240248-A1 Compositions and methods for targeted delivery of therapeutics using carriers Pending 03-Nov-2020 000000000
US-20230414525-A1 Compositions and methods for targeted delivery of therapeutics using carriers Pending 03-Nov-2020 A61K9/5015 0
To view Vesselon’s complete patent history, request access »

Vesselon Executive Team (4)

Name Title Board Seat Contact Info
Clayton Larsen Co-Founder, President & Chief Executive Officer
Rhodemann Li Co-Founder & Executive Vice President,of Finance & Strategy
Pier Claudio Ph.D Medical and Scientific Advisor
Neil Edwards Chief Financial Officer
To view Vesselon’s complete executive team members history, request access »

Vesselon Board Members (11)

Name Representing Role Since
Adam Levy Ph.D Self Board Member 000 0000
Earnest Schutt Self Chief Technical Advisor 000 0000
James Galeota Jr. Self Board Member 000 0000
Jared Weiss MD Self Clinical Advisor 000 0000
Joe Truitt Self Strategic Advisor 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Vesselon Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vesselon Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alliance Pharma Corporation Minority 000 0000 000000 0
Connecticut Innovations Venture Capital Minority 000 0000 000000 0
CTNext Accelerator/Incubator Minority 000 0000 000000 0
To view Vesselon’s complete investors history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »